澳柯瑪(600336.SH)控股股東擬集中競價減持不超1598.36萬股
格隆匯 8 月 28日丨澳柯瑪(600336.SH)公佈,因股東經營計劃和產業發展資金需求,公司控股股東青島市企業發展投資有限公司(以下簡稱"青島企發投")擬於2020年9月18日至2021年3月17日期間,通過集中競價交易方式減持不超過1598.36萬股通過非公開發行取得的公司股份,即減持數量不超過目前公司總股本的2%。若此次減持計劃實施期間公司總股本發生變化,青島企發投將根據計劃用於減持的股票比例對用於減持的股票數量進行相應調整。
截至本公告披露日,青島企發投共持有公司股份3.08億股,佔公司總股本的38.59%,全部為無限售流通股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.